Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-2 Gene-Modified TIL in Metastatic Melanoma
NCT00062036Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Jun 2003
- Primary completion
- Feb 2007
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of interleukin-2 gene-modified tumor infiltrating lymphocytes in melanoma, sponsored by National Institutes of Health. Started Jun 2003; status: completed.
02
Drugs
interleukin-2 gene-modified tumor infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00062036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062036.